Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

NCT00189345 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Neoplasms
Peritoneal Neoplasms

Interventions

BIOLOGICAL: anti-EpCAM x anti-CD3 (removab)

Sponsor

AGO Study Group